Mirabegron Stada (Mirabegron)

Mirabegron selectively activates β3‑adrenergic receptors located in the detrusor smooth muscle of the bladder. This activation raises cyclic AMP levels, causing the muscle to relax during the storage phase, which expands bladder capacity and lessens urgency and leakage.

The specific dose of Mirabegron Stada is determined by the prescribing healthcare professional based on the patient’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mirabegron in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Mirabegron Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) than anticholinergics. While anticholinergics block muscarinic receptors, mirabegron relaxes detrusor muscle via β3‑receptor stimulation. This distinction can result in a different side‑effect profile, with mirabegron often causing less dry mouth and constipation but potentially raising blood pressure.

Mirabegron Stada should be stored below 25 °C (77 °F) in its original container, protected from moisture and direct sunlight. Do not store in a bathroom or near a heat source, and keep the product out of reach of children.

Mirabegron Stada is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed, chewed, or split unless specifically instructed.

Serious risks include significant hypertension, angioedema, acute urinary retention that may require catheterisation, and rare cardiovascular events such as myocardial infarction. Patients should seek immediate medical attention if they experience severe headache, swelling of the face or throat, or inability to urinate.

Mirabegron Stada is contraindicated in patients with uncontrolled hypertension, severe urinary retention, or known hypersensitivity to mirabegron or any of its excipients. Caution is also advised for individuals with significant cardiovascular disease or those taking strong CYP3A4 or CYP2D6 inhibitors.